Mina Alsaraf Allo, PharmD, MPH
Vice President, Business Development Commercial Markets, Tempus
Mina Alsaraf Allo, PharmD, MPH
Vice President, Business Development Commercial Markets, Tempus
Mina Alsaraf Allo currently serves as Vice President, Business Development – Commercial Markets at Tempus Labs. There, she focuses on creating partnership with commercial payers and Tempus to ensure patient access to comprehensive genetic profiling for oncology and pharmacogenetic testing for psychiatry. Prior to Tempus, Mina served as Director, Health Economics and Outcomes Research Scientist at Bristol-Myers Squibb, covering national accounts leading medical value proposition discussions with access and organized customers and collaborations on real world retrospective observational research focused on total cost of care and precision medicine, impact of various quality improvement initiatives on overall patient outcomes and healthcare costs, and comparative effectiveness research.
Prior to joining BMS, Mina was Clinical Pharmacist – Pharmacoeconomics at Blue Cross Blue Shield of Michigan, where she focused on formulary management and design, specialty drug management, and quality improvement / Stars initiatives for the Medicare Advantage line of business and created provider and pharmacy pay-for-performance incentives to improve quality of care for beneficiaries. Mina is an active member of Academy of Managed Care Pharmacy (AMCP) and International Society for Pharmacoeconomics and Outcomes Research (ISPOR), serves as a peer reviewer for the Journal of Managed Care & Specialty Pharmacy, and served as the Education Co-Chair of the Midwest Affiliate of AMCP.
Mina received her Doctor of Pharmacy degree from Purdue University College of Pharmacy, completed a two-year post-doctoral fellowship through Rutgers University and Bristol-Myers Squibb in health policy and advocacy, and her Master of Public Health degree with a focus in Epidemiology at Harvard T.H. Can School of Public Health.
Trish Brown, MS
Director, AMR Payer Partner and Field Market Access Lead, Illumina
Trish Brown, MS
Director, AMR Payer Partner, Field Market Access Lead, Illumina
Trish Brown is a genetic counselor with over two decades of experience in clinical genetics. She is currently the Director, AMR Payer Partner & Field Market Access Lead at Illumina, leading the efforts for third party payer reimbursement of genomic testing in North and South America. Ms. Brown is experienced in commercialization of genomic tests, operations, and lab benefit management. Prior to joining Illumina, she has held executive leadership roles at distinguished corporations such as LabCorp and Medco, and the entrepreneurial successes DNA Direct, Fabric Genomics and BeaconLBS.
Rob Dumanois
Director, Reimbursement Strategy, Thermo Fisher Scientific
Rob Dumanois
Director, Reimbursement Strategy, Thermo Fisher Scientific
Rob has over 20 years’ experience working with payers, providers, and CLIA labs. His current role includes design and execution of reimbursement strategies for Oncomine™ Dx Target Test: the first FDA-approved next-generation sequencing (NGS) in vitro diagnostic test for non-small cell lung carcinoma (NSCLC), offering clinically actionable and analytical cancer-driver biomarker information to inform treatment decisions. This is a multi-marker companion diagnostic, developed in partnership with Pfizer and Novartis. Rob joined Thermo Fisher (formerly Life Technologies) in 2012, through an acquisition of Navigenics – where he led development and account growth of health plans, large employers, and voluntary benefit providers. Rob was also a Territory Vice President at RelayHealth, with duties that included payer-facing sales of solutions that included e-prescribing and webVisits. And prior to RelayHealth, Rob held senior sales and sales management positions with UnitedHealthcare.
Lauren Feldman, MHA
Vice President, Value, Access and Reimbursement, ADVI Health, LLC
Lauren Feldman, MHA
Vice President, Value, Access and Reimbursement, ADVI Health, LLC
Lauren joined ADVI in 2016 and serves as Vice President, overseeing and directing the firm’s reimbursement and market access work across life science and digital health clients. Lauren provides guidance for innovators looking to launch commercially or optimize coverage and reimbursement of an existing asset. She focuses on the evolving policy and regulatory paradigms to help clients anticipate and navigate the changing landscape.
Prior to joining ADVI, Lauren worked at the American Medical Association, where she drove strategy for emerging areas related to the CPT code set and the Health Solutions product portfolio. With a deep understanding of molecular clinical diagnostics, she led efforts to craft novel approaches to coding to meet the needs of an evolving market.
Earlier professional roles include clinical research and laboratory management at Harvard Medical School and Brigham and Women’s Hospital, and discovery research at Scholar Rock.
Steve Gardner, PhD
Chief Executive Officer, Precision Life Ltd.
Steve Gardner, PhD
Chief Executive Officer, Precision Life Ltd.
Steve has over 25 years’ experience building world-class teams, products and companies including as Global Director of Research Informatics for Astra. He has raised venture funding in the UK, EU and USA to develop and market highly innovative and commercially successful products in the life science, healthcare and food industries.
Steve was Global Director of Research Informatics for Astra. He has developed world-leading genomics, digital health, smart IoT and informatics technologies including several patented inventions. He was heavily involved in developing some of the core informatics systems used by major genomics companies during the initial Human Genome project and has worked extensively with major pharma companies on over 25 drug discovery and safety projects.
Steve specialises in AI enabled drug discovery and precision medicine, large-scale genomics, semantic data integration and complex data analytics for life science, healthcare and clinical decision support. Steve has served as an Advisory Council member for Breast Cancer Now and a Steering Committee member of the UKCRC Tissue Coordination Centre.
Robert C. Green, MD, MPH
Professor of Medicine;
Director, G2P Research Program;
Associate Director for Research, Partners Personalized Medicine
Division of Genetics, Department of Medicine
Brigham and Women’s Hospital, Broad Institute and Harvard Medical School
Robert C. Green, MD, MPH
Professor of Medicine; Director, G2P Research Program; Associate Director for Research, Partners Personalized Medicine, Division of Genetics, Department of Medicine, Brigham and Women’s Hospital, Broad Institute and Harvard Medical School
Robert C. Green, MD, MPH is a medical geneticist and physician-scientist who directs the G2P Research Program in translational genomics and health outcomes in the Division of Genetics at Brigham and Women’s Hospital and Harvard Medical School.
Dr. Green is principal investigator of the NIH-funded REVEAL Study, in which a cross-disciplinary team has conducted 4 separate multi-center randomized clinical trials since 2000, collectively enrolling 1100 individuals in order to explore emerging themes in translational genomics. Dr. Green also co-directs the NIH-funded PGen Study, one of the first prospective studies of direct-to-consumer genetic testing services. He is principal investigator of the MedSeq Project, the first NIH-funded randomized trial to explore the use of whole genome sequencing in the clinical practice of medicine and co-directs the BabySeq Project, the first NIH-funded trial of sequencing in newborns. The MedSeq and BabySeq Projects apply genome sequencing both in patients who are affected with hereditary disease and in those who are healthy, in order to study downstream impact on health, behavior and health care costs.
Dr. Green is currently Associate Director for Research of the Partners Center for Personalized Genetic Medicine, a Board Member of the Council for Responsible Genetics and a member of the Informed Cohort Oversight Boards for both the Children’s Hospital Boston Gene Partnership Program and the Coriell Personalized Medicine Collaborative. He was the lead author of the recently published recommendations from the American College of Medical Genetics and Genomics for management of incidental findings in clinical sequencing.
Mark D. Hiatt, MD, MBA, MS
Vice President, Medical Affairs, Guardant Health
Mark D. Hiatt, MD, MBA, MS
Vice President, Medical Affairs, Guardant Health
Mark Hiatt, currently Vice President for a precision oncology company, has served as the chief medical executive for a multi-state Blues plan and a national medical benefits manager, and departmental leader and board member for a regional health system. Dr. Hiatt completed a fellowship in cardiovascular imaging at Stanford University, residency in radiology and master’s in Health Evaluation Sciences at the University of Virginia, and MD and MBA with academic distinction at Wake Forest University. He is the recent chair of the Greater Salt Lake Chapter of the American Red Cross.
Howard J. Jacob, PhD
Vice President, Head of Genomic Research and Head of Data Convergence, AbbVie
Howard J. Jacob, PhD
Vice President, Head of Genomic Research and Head of Data Convergence, AbbVie
Howard Jacob, Ph.D., is Vice President, Head of Genomic Research and Head of Data Convergence at AbbVie, one of the world’s leading biopharmaceutical companies.
Dr. Jacob joined AbbVie in January 2018 to cultivate the company’s growing genomics program. An accomplished leader in the field of genetics and genomics, he has published more than 250 peer-reviewed articles in his academic career, focusing on the genetic mapping of complex diseases and building genomic resources and tools to better understand the functional impact of genetic variation. As Head of Data Convergence, he pushes AbbVie’s data and digital strategy forward by connecting resources and expertise within the company’s R&D function – including genomics, external data and clinical and real world evidence – to drive insights into the discovery, development and commercialization of new therapies for patients.
Throughout his career, Dr. Jacob has been a pioneer in translating research into the healthcare ecosystem, bringing genomic medicine to patients in need of answers. In 2009, Dr. Jacob and his team at the Medical College of Wisconsin were the first to use genomic sequencing to save a patient’s (Nicholas Volker) life. Nicholas’ story was highlighted in a Pulitzer Prize winning series in the Milwaukee Journal Sentinel.
Prior to his role at AbbVie, Dr. Jacob served as the Executive Vice President for Genomic Medicine, Chief Genomics Medicine Officer and Faculty Investigator at the HudsonAlpha Institute for Biotechnology. Dr. Jacob led the whole genome sequencing core for the NIH-funded Undiagnosed Disease Network and led the clinical teams at the world’s first stand-alone genomic medicine clinic, as well as a whole genome clinical sequencing lab. Prior to his role there, Dr. Jacob was the founding director of the Human and Molecular Genetics Center at Medical College of Wisconsin, which grew from two to a team of 30 faculty members. He has also founded four companies and participated on the advisory boards for numerous academic and commercial organizations.
Dr. Jacob’s passion for improving the lives of critically ill patients has been the catalyst for his determination to bring whole genome sequencing into the clinical setting to affect patient care, and in his new role to discover therapeutic solutions for some of the most difficult diseases. He earned his Ph.D. at the University of Iowa and did post-doc research with Eric Lander and Victor Dzau at MIT, Harvard and Stanford.
Eugean Jiwanmall, MBA, MPH
Senior Research Analyst, Medical Policy & Technology Evaluation, Independence Blue Cross
Eugean Jiwanmall, MBA, MPH
Senior Research Analyst, Medical Policy & Technology Evaluation, Independence Blue Cross
As a Senior Research Analyst for Medical Policy and Technology Evaluation for Independence Blue Cross, Eugean Jiwanmall has served as subject-matter expert, writer, reviewer, communicator, presenter, consultant, adviser, facilitator, and decision maker for hundreds of medical policy topics and technology assessments spanning dozens of clinical disciplines and multiple business areas.
Eugean holds a bachelor’s in biological sciences with honors from Drexel University, master’s of public health in evaluative clinical sciences from Dartmouth Medical School, and MBA in healthcare management and economics with honors from Drexel University, and is completing graduate studies in bioethics at the University of Pennsylvania School of Medicine.